IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i1p27-34.html
   My bibliography  Save this article

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

Author

Listed:
  • László Gulácsi
  • Fanni Rencz
  • Márta Péntek
  • Valentin Brodszky
  • Ruth Lopert
  • Noémi Hevér
  • Petra Baji

Abstract

While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data. Copyright Springer-Verlag Berlin Heidelberg 2014

Suggested Citation

  • László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:27-34
    DOI: 10.1007/s10198-014-0591-7
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-014-0591-7
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-014-0591-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Cécile Gaujoux-Viala & Bruno Fautrel, 2012. "Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis," PharmacoEconomics, Springer, vol. 30(12), pages 1145-1156, December.
    2. Imre Boncz & Júlia Nagy & Andor Sebestyén & László Kőrösi, 2004. "Financing of health care services in Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(3), pages 252-258, September.
    3. Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott, 2012. "Golimumab for the Treatment of Psoriatic Arthritis," PharmacoEconomics, Springer, vol. 30(4), pages 257-270, April.
    4. László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga, 2014. "Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 13-25, May.
    5. L. Gulácsi & E. Orlewska & M. Péntek, 2012. "Health economics and health technology assessment in Central and Eastern Europe: a dose of reality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 525-531, October.
    6. John Nixon & Stephen Rice & Michael Drummond & Stephanie Boulenger & Philippe Ulmann & Gerard Pouvourville, 2009. "Guidelines for completing the EURONHEED transferability information checklists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(2), pages 157-165, May.
    7. Lopert, Ruth & Ruiz, Francis & Chalkidou, Kalipso, 2013. "Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania," Health Policy, Elsevier, vol. 112(3), pages 202-208.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    2. García-Mochón, Leticia & Espín Balbino, Jaime & Olry de Labry Lima, Antonio & Caro Martinez, Araceli & Martin Ruiz, Eva & Pérez Velasco, Román, 2019. "HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey," Health Policy, Elsevier, vol. 123(2), pages 182-190.
    3. Ben Kearns & Myfanwy Lloyd Jones & Matt Stevenson & Chris Littlewood, 2013. "Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(6), pages 479-488, June.
    4. Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012. "Bevacizumab for Metastatic Colorectal Cancer," PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
    5. László Gulácsi, 2014. "Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 1-4, May.
    6. Nicholas Latimer & Christopher Carroll & Ruth Wong & Paul Tappenden & Michael Venning & Raashid Luqmani, 2014. "Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 32(12), pages 1171-1183, December.
    7. Csanádi, Marcell & Kaló, Zoltán & Rutten-van Molken, Maureen & Looman, Willemijn & Huic, Mirjana & Ercevic, Darija & Atanasijevic, Dragana & Lorenzovici, László & Petryszyn, Paweł & Pogány, Gábor & Pi, 2022. "Prioritization of implementation barriers related to integrated care models in Central and Eastern European countries," Health Policy, Elsevier, vol. 126(11), pages 1173-1179.
    8. Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Carmelo Juárez-Castelló, 2012. "Coping with uncertainty on health decisions: assessing new solutions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 375-378, August.
    9. Eleftherios Sideris & Mark Corbett & Stephen Palmer & Nerys Woolacott & Laura Bojke, 2016. "The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(11), pages 1101-1110, November.
    10. Elena Olariu & Wael Mohammed & Yemi Oluboyede & Raluca Caplescu & Ileana Gabriela Niculescu-Aron & Marian Sorin Paveliu & Luke Vale, 2023. "EQ-5D-5L: a value set for Romania," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 399-412, April.
    11. Rotar, Alexandru M. & Preda, Alin & Löblová, Olga & Benkovic, Vanesa & Zawodnik, Szymon & Gulacsi, Laszlo & Niewada, Maciej & Boncz, Imre & Petrova, Guenka & Dimitrova, Maria & Klazinga, Niek, 2018. "Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries," Health Policy, Elsevier, vol. 122(3), pages 230-236.
    12. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    13. Nystrand, Camilla & Gebreslassie, Mihretab & Ssegonja, Richard & Feldman, Inna & Sampaio, Filipa, 2021. "A systematic review of economic evaluations of public health interventions targeting alcohol, tobacco, illicit drug use and problematic gambling: Using a case study to assess transferability," Health Policy, Elsevier, vol. 125(1), pages 54-74.
    14. Jonathan Tosh & Rachel Archer & Sarah Davis & Matt Stevenson & John Stevens, 2013. "Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(8), pages 653-661, August.
    15. Eldon Spackman & Stephen Rice & Gill Norman & Dong-Churl Suh & Alison Eastwood & Stephen Palmer, 2013. "Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer," PharmacoEconomics, Springer, vol. 31(3), pages 185-194, March.
    16. Lesley Uttley & Ben Kearns & Shijie Ren & Matt Stevenson, 2013. "Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(11), pages 981-990, November.
    17. Pepijn Vemer & Maureen Rutten-van Mölken, 2011. "Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(5), pages 397-404, October.
    18. Fernando Antoñanzas & Robert Terkola & Maarten Postma, 2016. "The Value of Medicines: A Crucial but Vague Concept," PharmacoEconomics, Springer, vol. 34(12), pages 1227-1239, December.
    19. Peter Gaal & Nóra Stefka & Júlia Nagy, 2006. "Cost accounting methodologies in price setting of acute inpatient services in Hungary," Health Care Management Science, Springer, vol. 9(3), pages 243-250, August.
    20. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:27-34. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.